4.7 Article

The Role of Nutraceuticals in Statin Intolerant Patients

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 72, Issue 1, Pages 96-118

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.04.040

Keywords

cardiovascular risk; dyslipidemia; nutraceuticals; position paper; statin intolerance

Funding

  1. Sanofi
  2. Valeant
  3. Amgen
  4. Angelini
  5. Boehringer Ingelheim
  6. Meda
  7. Merck Sharp Dohme
  8. AstraZeneca
  9. KRKA
  10. Pfizer
  11. Vifor Pharma
  12. Bayer
  13. Brahms
  14. Chugai Pharma
  15. Roche
  16. Novartis
  17. WinMedica
  18. Pharma
  19. Chemistry Competence Center of Latvia
  20. Libytec
  21. Aegerion
  22. Akcea
  23. Amarin
  24. Duke
  25. Esperion
  26. Eliaz Therapeutics
  27. FH Foundation
  28. Gemphire
  29. Ionis
  30. Kaneka
  31. Kastle Therapeutics
  32. Kowa
  33. RegenXBio
  34. Sanofi/Regeneron
  35. Stage 2 Innovations
  36. University of Penn
  37. Zydus Discovery
  38. Regeneron
  39. Bristol-Myers Squibb/Pfizer
  40. Servier
  41. Abbott
  42. Actavis
  43. Genzyme
  44. SanofiRegeneron
  45. Eli Lilly
  46. Meda Pharma
  47. Novo Nordisk
  48. Roche Diagnostics

Ask authors/readers for more resources

Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non-lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction. (C) 2018 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available